Friday, August 10, 2012

Caring for Patients with Dementia and Diabetes


ADA 2012 Conference, presented by Jamehl Demons, MD

-       Diabetes – Risk factor for cognitive impairment
o   Known risk factors for cerebrovascular disease
§  RR 1.51 for developing vascular dementia
o   DM and Alzheimer’s dementia – RR 1.21 for AD (10 out of 19 studies showed it was a risk factor
o   DM associated with cognitive decline
-       Does treating DM prevent dementia?
-       AGS guidelines for care of the older people with DM
o   Importance of individualized goal-setting
o   Frail older adults and life expectancy < 5 yrs
§  Risks of intensive glycemic control may outweigh benefits
§  Consider HbA1c target of 8%
-       Stages of Dementia
o   Mild
§  Stage 1: no difficulty
§  Stage 2: forgetting location of objects
o   Moderate
§  Stage 3: difficulty traveling to new places
§  Stage 4: IADLS
§  Stage 5: needs assistance to choose clothing
o   Severe
§  Stage 6: need help with ADLS
§  Stage 7: loss of speech, mobility, change in consciousness
-       Dementia patients in nursing homes
o   Most are in severe stages of disease
o   Frail: accumulation of multiple chronic illnesses associated with vulnerabilities including but not limited to dementia and cognitive impairment
o   Poor life expectancy: average life expectance from diagnosis 4.5 years
-       Individualized treatment plan
o   Multidisciplinary team approach
o   Assessment of prior treatment approach
§  Cognitive status
§  Ability to note hypoglycemia symptoms
-       Hyperglycemia
o   Dehydration
§  Increased risk in elderly; decreased intake, decreased thirst mechanism
o   Visual disturbances
o   Confusion
-       Hypoglycemia
o   Risk factors
§  Age
§  Renal insufficiency
§  Long acting oral agents
§  Poor nutrition – decreased muscle mass
§  CHF
§  Recent hospitalization
§  Polypharmacy
o   Decreased balance and falls
o   Cardiovascular events may be precipitated in prolong hypoglycemia
o   Altered renal function may later breakdown of medications
-       Persons with dementia are less able to communicate symptoms
-       Nutritional intake
o   Variable intake – may require adjustments to medications
o   Dysphagia
§  Often less hydrated leading to renal insufficiencies
§  Pre-mixed thickened foods have increased carbohydrate load
o   Tube feeding
§  Adjust the formula to provide low carbohydrate load
-       Treatment guideline (American Medical Directors Association)
o   Treatment goals should be more relaxed if:
§  Severe dementia
§  Life expectancy < 5 years
§  Anorexia or inability to feed self
§  Malignancy
§  Lack of awareness of hypoglycemia
-       Nursing Home management of DM
o   Insulin sliding scale not effective
§  More hypoglycemia by treating blood sugar now based on prior treatment rather than future need
§  Insulin sliding scale is still be used (54% in chart review of 5000 NH pts)

Starting insulin without sliding scale
Step
Insulin
Oral Medications
Advance to Next stop when A1c > 7.0% and:
1
Start glargine, detemir or evening NPH.
Titrate dose until Fasting PG < 120mg/dL (6.7mmol/L)
Continue all
Fasting PG at target but prandial or postprandial is higher than target
2
Add bolus insulin before main meal (usually evening meal)
Continue metformin
Continue TZDs?
Stop SUs?
Capillary glucose before main meal is higher than fasting value
3
Add bolus insulin before a second meal (usually first meal of the day)
Same
Capillary glucose highest after third (uncovered) meal
4
Add bolus insulin before remaining meal.
Adjust dosages based on home PG
Same
-
NPH=neutral protamine Hagedorn; PG=plasma glucose, SUs=sulfonylureas, TZDs=thiazolidinediones
Adapted from Karl DM. The use of bolus insulin and advancing insulin therapy in type 2 diabetes. Curr Diab Rep. Philadelphia. Current Medicine Group, LLC. 2004
J Am Med Dire Assoc 2007;8:502-10.

Implementing a Hyperglycemic Management Program for Complex Older Patients


ADA 2012 Conference, presented by Barbara Resnick, MD

-       General principles of diabetes management
o   Older adults with relatively good health should have the same opportunity as younger adults for intensive diabetes management, reduction of risks associated with diabetes, and treatment of comorbid conditions
o   For some older patients, intensive management of diabetes and its complications may be logistically difficult, may not provide benefit, may not be consistent with patient preferences and in some patients, may even be harmful
o   Diabetes management goals and clinical targets should be individualized
-       Clinical evaluation of complex older adults with diabetes
o   Evaluate risk factors for atherosclerotic disease and presence of comorbid diseases
o   Take thorough medication history
o   Assess functional status
o   Screen for geriatric syndromes: use of multiple medications, depression, cognitive impairment, urinary incontinence, injurious falls, and chronic pain
o   Assess need for diabetes education and self-management support, and whether to involve a caregiver
o   Assess resident priorities and preferences
-       Challenges to DM management/ prevention of hyperglycemia
o   Resident-specific issues
o   Provider specific issues
o   System related issues
§  NO direction impact of poor diabetic management à patients don’t feel it
§  Lac of standards or guidelines for optimal management of diabetes across the full aging continuum
§  Behaviour change is never easy…I know I should, but….
§  Practitioners’ ambivalence about the benefits and risks of glycemic control
§  Knowledge deficiencies among direct caregivers/families/residents/non-geriatric focused PCPs
§  Inadequate metabolic monitoring and review of treatment by the practitioner
§  Changing old beliefs as new knowledge is gained
§  Getting the story straight (how much and when did the patient eat?)
-       Tidbits for successful behaviour change
o   Don’t be afraid to address multiple behaviours
§  Addressing multiple behavious allows you to teach general behaviour change principles such as how to cope with barriers, work with a partner, or establish goals and rewards
§  Older individuals tend to choose to change multiple behaviours rather than focus on a single behaviour
§  Providers can change although work off what they believe more so than what they know
-       Process for change
o   Component I
§  Education
·      To assure a philosophy of care that increases awareness and concerns about hyperglycemia
§  Does the environment facilitate management of diabetes and hyperglycemia
·      Equipment
·      Sufficient staffing
·      Exercise equipment and environment to support and encourage physical activity
§  Specific issues to teach to facilitate adherence
·      Caregivers and older adults less likely to be familiar with
o   Atypical presentation of hyperglycemia
o   Give tickler sheets of exactly what to look for
§  Confusion, delirium, feel lousy
§  Blurred vision (eyesight)
§  Feeling very tired
§  Frequent urination
§  Leg cramps
§  More thirsty than usual
§  Weight loss
§  Dry eyes or mouth
§  Weakness
§  Dizziness
§  Drowsiness or confusion/seizures
§  At the institutional level
·      Teach patients/caregivers to assess for underlying cause of episodes of hyperglycemia – be a detective
·      Teach rational for testing sugars at times
·      Teach recognition of associated complications from DM (wounds, fungal infection, memory changes)
·      Review drug side effects à compliance
·      Explore behaviours: ETOH, diet, exercise, meds
o   Focused on outcomes – decrease wine and cake intake
o   Repeat, repeat, and repeat – each visit give hyperglycemia prevention tidbits, trivia questions to staff
o   What to eat and what not to eat
o   What exercise to do and what not to do
·      EASY website
·      NIA workout to go
o   Component II
§  Evaluation of the resident and goal setting
§  Establish goals for residents and settings
·      Look at status of individual and mean glucose
·      Look at hospitalization/ER visits for individual settings
·      Decreasing fingerpricks?
·      Survey issues around medication management
§  Need to help establish and accept realistic treatment goals
·      Explore goals with residents/family – which way do they want to go?
·      Optimal QOL – no versus some dietary management; some exercise; ETOH use, medication adherence
·      Avoidance of hypo or marked hyperglycemia
·      Control of complications?
·      Decreased hospitalizations
·      Focus on symptom management
o   Tie symptoms (e.g., increased urination, dry mouth, confusion) to sugars
·      Interpersonal Interactions
o   Verbal encouragement
§  Start with encouragement and reinforcement
§  Find a buddy/family member to help motivate
§  Physical encouragement via performance – tie adherence to positive outcomes (weight loss à less hyperglycemic episodes, reduce meds, etc)
§  If no change in 6 weeks to 6 months (depending on visit schedule) move on to tough love
§  Encouragement tied to outcomes
§  Threat of meds
·      Eliminate the unpleasant sensations
o   Address the common ones
§  Pain
§  Fear of falling
§  Staff fear causing hypoglycemia
§  Fatigue
§  Hunger
§  Finances
§  Ask what stops them
§  Observe what stops them
§  Differentiate barriers from excuses
·      Role modeling
o   Share your own challenges and successes in diet, exercise and mediation adherence
o   Eat, play, and engage in physical activity with residents and encourage families to do likewise
·      Weigh real world issues with medication management
o   Carefully weigh the benefit/risk of medications to determine how badly this is needed
o   Can alternative methods of administration be considered?
§  Diet vs. pill, insulin pens, daily dosing
o   Component III
§  Mentoring and motivating of everyone

Wednesday, July 25, 2012

Patient-Centered Approach to Type 2 Diabetes

Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Glycemic Targets:

1. Target HbA1c < 7.0%

  • In most patients to reduce the incidence of microvascular disease
  • Mean plasma glucose of ~ 8.3-8.9 mmol/L
  • Fasting and premeal glucose < 7.2mmol/L
  • Postprandial glucose < 10 mmol/L

2. Target more stringent HbA1c (e.g., 6.0-6.5%)

  • In selected patients such as short disease duration, long life expectancy, no significant cardiovascular disease (CVD) if this can be achieved without significant hypoglycemia or other adverse effects of treatment

 

3. Target less stringent HbA1c (e.g., 7.5-8.0% or even slightly higher)

  • In patients with history of severe hypoglycemia, limited life expectancy, advanced complications, extensive comorbid conditions and those in whom the target is difficult to attain despite intensive self-managment education, repeated counseling, and effective doses of multiple gluocse-lowering agents, including insulin.

 

Reference:

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;25:1364-79

Friday, July 13, 2012

Exendin - A New Incretin?

ADA June 2012 Conference


Alpha cells and the origin of glucagon-like sequences and their receptors

David M. Irwin, Department of Laboratory Medicine and Pathobiology, University of Toronto


Summary of presentation:

Incretin Hormones – 2 known human incretin hormones
-          Glucagon-like peptide 1 (GLP-1)
-          Glucose-dependent insulinotropic peptide (GIP)

Other incretins = Exendin
-          Long acting GLP-1 analogue
o   Acts through the GLP-1 receptor
o   Have increased circulating half-life
o   Synthetic version marketed
-          From the venom of a lizard (Gila monster)
-          No known orthologs in vertebrates, not a product of the proglucagon gene
-          Anole Lizard Exendin – sequence of peptides are not similar to GLP-1 or GIP (human genome)
-          Other animals had similar exendin to lizard (chicken, turkey, duck, zebra finch, xenopus)
-          Exendin 1, 2, 3,and 4 sequences – exendin 3 and 4 are GLP-1 like in their sequence and function; exendin 1 and 2 similar to the are GIP-like in sequence and function
-          Expression of the exendin gene in the chicken and xenopus brain – who knows what it is duing there?
-          No exendin gene in human genome!
-          Exendin genes are found in birds, reptiles and frogs
-          No obvious candidate receptor for exendin; glucagon, GLP1, GLP2, and GIP act through related receptors
-          There are novel group of receptors present in fish, reptiles, birds that are NOT present in mammals – why do mammals not have this gene?
-          GLP1 receptors not found in fish
-          GCGR – duplicated in fish (glucagon receptors)
-          GLP2R – single copy in all species
-          GIPR – no intact gene found in birds
-          GRLR – not found in mammals (glucagon-receptor-like-receptors

Conclusion
o   Genomic data useful for identifying new genes
o   Continues to yield surprises
o   Hormone and receptor families are larger and more complex
-          Open questions
o   What does exendin do in other vertebrates?
o   Is GRLR the receptor for exendin?
o   Why do humans (all mammals) not have Exendin/GRLR?
o   What ligand/receptor has replace the function of Exendin/GRLR in mammals?